| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
|
Tamura T.;Morita S;Lim W.T;Cheng Y;Ichinose Y;Maemondo M;Chang J;Goto K;Takahashi T;Nishio M;Sugawara S;Chih-Hsin Yang;Soo R.A;Zhang L;Shi Y.K;Yamamoto N;Nakagawa K;Mok T.S.K;Lu S;Nokihara H; Nokihara H; Lu S; Mok T.S.K; Nakagawa K; Yamamoto N; Shi Y.K; Zhang L; Soo R.A; CHIH-HSIN YANG; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim W.T; Morita S; Tamura T. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
|
Bai Y; Rabbie S; Kim D.-W; Ahn M.-J; CHIH-HSIN YANG; Zhang X.; Zhang X.;Chih-Hsin Yang;Ahn M.-J;Kim D.-W;Rabbie S;Bai Y;Yin X;Xu Y;Cheng Z;Zhang L;Chen K;Wang Y;Guo Q;Yang Z; Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
|
Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-15T07:01:20Z |
Rock record and magnetic response to large earthquakes within Wenchuan Earthquake Fault Scientific Drilling cores
|
Zhang, L.;Sun, Z.;Li, H.;Zhao, L.;Song, S.-R.;Chou, Y.-M.;Cao, Y.;Ye, X.;Wang, H.;He, X.; Zhang, L.; Sun, Z.; Li, H.; Zhao, L.; Song, S.-R.; Chou, Y.-M.; Cao, Y.; Ye, X.; Wang, H.; He, X.; SHENG-RONG SONG |
| 臺大學術典藏 |
2020-05-15T07:00:48Z |
A 60-year record of 129I in Taal Lake sediments (Philippines): Influence of human nuclear activities at low latitude regions
|
Zhang, L.; Hou, X.; Li, H.-C.; Xu, X.; HONGCHUN LI |
